"Imipramine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
| Descriptor ID |
D007099
|
| MeSH Number(s) |
D03.633.300.240.485
|
| Concept/Terms |
Imipramine- Imipramine
- Norchlorimipramine
- Imidobenzyle
|
Below are MeSH descriptors whose meaning is more general than "Imipramine".
Below are MeSH descriptors whose meaning is more specific than "Imipramine".
This graph shows the total number of publications written about "Imipramine" by people in this website by year, and whether "Imipramine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 1 | 3 |
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imipramine" by people in Profiles.
-
Li Y, Lu Z, Zhang L, Kirkwood CL, Kirkwood KL, Lopes-Virella MF, Huang Y. Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss. J Periodontal Res. 2022 Jan; 57(1):173-185.
-
Arias HR, Fedorov NB, Benson LC, Lippiello PM, Gatto GJ, Feuerbach D, Ortells MO. Functional and structural interaction of (-)-reboxetine with the human a4ß2 nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 2013 Jan; 344(1):113-23.
-
Osawa Y, Uchinami H, Bielawski J, Schwabe RF, Hannun YA, Brenner DA. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem. 2005 Jul 29; 280(30):27879-87.
-
Thiedke CC. Nocturnal enuresis. Am Fam Physician. 2003 Apr 01; 67(7):1499-506.
-
Nordahl TE, Stein MB, Benkelfat C, Semple WE, Andreason P, Zametkin A, Uhde TW, Cohen RM. Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. Biol Psychiatry. 1998 Nov 15; 44(10):998-1006.
-
Katschnig H, Amering M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull. 1996; 32(1):149-55.
-
Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, et al. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
-
Brady KT, Lydiard RB, Kellner CH, Joffe R, Laird LK, Morton WA, Steele TE. A comparison of the effects of imipramine and fluvoxamine on the thyroid axis. Biol Psychiatry. 1994 Dec 01; 36(11):778-9.
-
Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, Geraci MF, Black BC, Uhde TW, Waclawiw MA, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994 May 19; 330(20):1411-7.
-
Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry. 1993 Jul; 150(7):1125-6.